Effective suppression of atrial fibrillation by ivabradine: Novel target for an established drug?
- 1 June 2017
- journal article
- Published by Elsevier in International Journal of Cardiology
- Vol. 236, 237-243
Abstract
No abstract availableKeywords
Funding Information
- German Cardiac Society
- Dr. Peter Osypka Foundation
This publication has 32 references indexed in Scilit:
- Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillationInternational Journal of Cardiology, 2016
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure, 2016
- Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise toleranceInternational Journal of Cardiology, 2016
- Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4Journal of Molecular and Cellular Cardiology, 2015
- hERG Potassium Channel Blockade by the HCN Channel Inhibitor Bradycardic Agent IvabradineJournal of the American Heart Association, 2015
- Combined Actions of Ivabradine and Ranolazine Reduce Ventricular Rate During Atrial FibrillationJournal of Cardiovascular Electrophysiology, 2014
- If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillationHeart Rhythm, 2014
- Novel molecular targets for atrial fibrillation therapyNature Reviews Drug Discovery, 2012
- Atrial Remodeling and Atrial FibrillationCirculation: Arrhythmia and Electrophysiology, 2008
- The Heart Rate‐Lowering Agent Ivabradine Inhibits the Pacemaker Current Ifin Human Atrial MyocytesJournal of Cardiovascular Electrophysiology, 2007